Reports
Sale
Male Hypogonadism Market Size, Share, Analysis, Forecast: By Type: Primary Hypogonadism, Secondary Hypogonadism; By Diagnosis: Blood Tests, Imaging Scans, Genetic Testing, Clinical Evaluation; By Therapy; By Drug Delivery; By End User; Regional Analysis; Regulatory Framework; Patent Analysis; Supplier Landscape; 2024-2032
Male Hypogonadism Market Outlook
The male hypogonadism market size is expected to grow at a CAGR of 3.6% during the forecast period of 2024-2032, driven by the rising prevalence of male hypogonadism, growing elderly population size, and heightened awareness among patients across the 8 major markets.
Male Hypogonadism Market Overview
Male hypogonadism is characterized by the low production of the male sex hormone testosterone, resulting in testosterone deficiency in the body. The prevalence of the condition is estimated to be 6% to 12% in the general population and is found to increase with age. It is reported that the prevalence rate of male hypogonadism is 40% in men having type 2 diabetes , suggesting a strong correlation between hypogonadism and type 2 diabetes. With the growing number of cases of testicular failure, the male hypogonadism market demand is projected to witness a surge in the forecast period.
The evolving regulatory frameworks characterised by surge in approvals from the health regulatory agencies are positively influencing the market growth. In October 2023, Eugia Pharma Specialities Limited, the subsidiary of Aurobindo Pharma , received its final approval from the United States Food and Drug Administration (FDA) to produce and commercialize Testosterone Cypionate injection. The product will be available in concentrations of 100 mg/mL and 200 mg/mL in multi-dose vials and 200 mg/mL in single-dose vials. The launch is scheduled for November 2023, and this is the 169th abbreviated new drug application (ANDA) approval received from Eugia Pharma Speciality Group (EPSG) facilities. Testosterone Cypionate injection is intended for replacement therapy in males with low or absent endogenous testosterone, such as primary hypogonadism.
The market is also driven by the growing geriatric population which is at a higher risk of developing male hypogonadism. In addition, the rising awareness among the patients coupled with investments and advancements in the healthcare sector will also fuel the market demand.
Male Hypogonadism Market Trends
| Key Trend | Impact |
| Advancements in Testosterone Replacement Therapy (TRT) | The significant advancements in testosterone replacement therapy options, including oral medications, transdermal patches, gels, and injections have resulted in minimized side effects, and more stable testosterone levels. |
| Increasing Awareness and Diagnosis Rates | Heightened awareness among both patients and healthcare providers about male hypogonadism is leading to higher diagnosis rates and a larger patient population seeking treatment. |
| Development of Novel Therapeutics | The market is witnessing the development of novel therapeutic agents, including selective androgen receptor modulators (SARMs) and new hormone synthesis inhibitors, offering potential alternatives to traditional TRT. |
| Personalized Treatment Approaches | There is an increasing emphasis on personalized medicine within the market, focusing on individual patient needs, risk profiles, and preferences to optimize treatment outcomes. |
Male Hypogonadism Market Segmentation
Market Breakup by Type
- Primary Hypogonadism
- Secondary Hypogonadism
The market is segmented by type into primary hypogonadism and secondary hypogonadism. Primary hypogonadism involves dysfunction of the testes whereas secondary hypogonadism occurs due to a dysfunction in the hypothalamus or pituitary gland.
Market Breakup by Diagnosis
- Blood Tests
- Imaging Scans
- Genetic Testing
- Clinical Evaluation
By diagnosis, the market is segmented into blood tests, imaging scans, genetic testing, and clinical evaluation. These diagnostic approaches help to determine appropriate treatment for individuals with hypogonadism.
Market Breakup by Therapy
- Testosterone Replacement Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Hormone Replacement Therapy
- Assisted Reproductive Technologies (ART)
The male hypogonadism market share offers therapies such as testosterone replacement therapy, selective estrogen receptor modulators (SERMs), hormone replacement therapy, and assisted reproductive technologies (ART). These therapies help to address the challenges associated with hypogonadism.
Market Breakup by Drug Delivery
- Topical Gels
- Injectables
- Transdermal Patches
- Others
The market for male hypogonadism is segmented by drug delivery methods into topical gels, injectables, transdermal patches, and others. This market segment represents diverse options available for administering testosterone replacement therapy and other treatment therapies.
Market Breakup by End User
- Hospitals and Clinics
- Specialty Clinics
- Retail Pharmacies
- Others
The male hypogonadism market report provides an insight into end users of the market as well. It includes hospitals and clinics, specialty clinics, retail pharmacies, and other healthcare facilities. This market segment includes diverse healthcare settings that provide treatment options for patients with male hypogonadism.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China. North America holds a high market value due to the rising cases of individuals with male hypogonadism. Furthermore, the rising awareness among patients and greater accessibility to treatment therapies are also driving the market demand.
Male Hypogonadism Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Lipocine Inc.
- Pfizer Inc
- AbbVie Inc
- Aytu BioPharma Inc.
- Merck & Co., Inc.
- Laboratoires Genevrier
- Ferring
- Perrigo Company plc
- Eli Lilly
- Bayer AG
- Endo International plc.
- Allergan plc
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- IBSA Institute Bio Chimique SA
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Therapy |
|
| Breakup by Drug Delivery |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Male Hypogonadism Market Report
- What is the projected growth of the male hypogonadism market over the forecast period?
- What are the primary factors driving the growth of the market?
- What are the main challenges or barriers hindering the growth of the market?
- What type of male hypogonadism will dominate the market share?
- Which diagnostic method is expected to have a high market value in the coming years?
- Which drug delivery method will experience the highest demand in the market segment?
- What are the emerging trends and innovations in the market?
- What is the regulatory landscape governing the market?
- How does the prevalence of male hypogonadism impact the market growth?
- What are the current therapies available for male hypogonadism? Which therapy is expected to boost the male hypogonadism market value?
- How are healthcare expenditure patterns affecting the adoption of treatments for male hypogonadism?
- What is the competitive landscape of the male hypogonadism market, and who are the major players?
- What are the regional dynamics influencing the market growth?
- How are advancements in diagnostic technologies impacting the diagnosis and treatment of male hypogonadism?
- What are the key strategies adopted by market players?
- How are awareness campaigns affecting the diagnosis and treatment patterns related to male hypogonadism?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Male Hypogonadism Market Overview- 8 Major Markets
3.1 Male Hypogonadism Market Historical Value (2017-2023)
3.2 Male Hypogonadism Market Forecast Value (2024-2032)
4 Male Hypogonadism Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Male Hypogonadism Epidemiology Analysis – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032)
6.5 China Male Hypogonadism Epidemiology Scenario and Forecast (2017-2032
7 Male Hypogonadism Market Landscape*- 8 Major Markets
7.1 Male Hypogonadism Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Male Hypogonadism Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Therapy
7.2.3 Analysis by Drug Delivery
8 Male Hypogonadism Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Male Hypogonadism Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Male Hypogonadism Market Segmentation (2017-2032) – 8 Major Markets
11.1 Male Hypogonadism Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Primary Hypogonadism
11.1.3 Secondary Hypogonadism
11.2 Male Hypogonadism Market (2017-2032) by Diagnosis
11.2.1 Market Overview
11.2.2 Blood Tests
11.2.3 Imaging Scans
11.2.4 Genetic Testing
11.2.5 Clinical Evaluation
11.3 Male Hypogonadism Market (2017-2032) by Therapy
11.3.1 Market Overview
11.3.2 Testosterone Replacement Therapy
11.3.3 Selective Estrogen Receptor Modulators (SERMs)
11.3.4 Hormone Replacement Therapy
11.3.5 Assisted Reproductive Technologies (ART)
11.4 Male Hypogonadism Market (2017-2032) by Drug Delivery
11.4.1 Market Overview
11.4.2 Topical Gels
11.4.3 Injectables
11.4.4 Transdermal Patches
11.4.5 Others
11.5 Male Hypogonadism Market (2017-2032) by End User
11.5.1 Market Overview
11.5.2 Hospitals and Clinics
11.5.3 Specialty Clinics
11.5.4 Retail Pharmacies
11.5.5 Others
11.6 Male Hypogonadism Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 China
12 United States Male Hypogonadism Market (2017-2032)
12.1 United States Male Hypogonadism Market Historical Value (2017-2023)
12.2 United States Male Hypogonadism Market Forecast Value (2024-2032)
12.3 United States Male Hypogonadism Market (2017-2032) by Type
12.3.1 Market Overview
12.3.2 Primary Hypogonadism
12.3.3 Secondary Hypogonadism
12.4 United States Male Hypogonadism Market (2017-2032) by Diagnosis
12.4.1 Market Overview
12.4.2 Blood Tests
12.4.3 Imaging Scans
12.4.4 Genetic Testing
12.4.5 Clinical Evaluation
13 EU-4 and United Kingdom Male Hypogonadism Market (2017-2032)
13.1 EU-4 and United Kingdom Male Hypogonadism Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Male Hypogonadism Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Male Hypogonadism Market (2017-2032) by Type
13.3.1 Market Overview
13.3.2 Primary Hypogonadism
13.3.3 Secondary Hypogonadism
13.4 EU-4 and United Kingdom Male Hypogonadism Market (2017-2032) by Diagnosis
13.4.1 Market Overview
13.4.2 Blood Tests
13.4.3 Imaging Scans
13.4.4 Genetic Testing
13.4.5 Clinical Evaluation
14 Japan Male Hypogonadism Market (2017-2032)
14.1 Japan Male Hypogonadism Market Historical Value (2017-2023)
14.2 Japan Male Hypogonadism Market Forecast Value (2024-2032)
14.3 Japan Male Hypogonadism Market (2017-2032) by Type
14.3.1 Market Overview
14.3.2 Primary Hypogonadism
14.3.3 Secondary Hypogonadism
14.4 Japan Male Hypogonadism Market (2017-2032) by Diagnosis
14.4.1 Market Overview
14.4.2 Blood Tests
14.4.3 Imaging Scans
14.4.4 Genetic Testing
14.4.5 Clinical Evaluation
15 China Male Hypogonadism Market (2017-2032)
15.1 China Male Hypogonadism Market Historical Value (2017-2023)
15.2 China Male Hypogonadism Market Forecast Value (2024-2032)
15.3 China Male Hypogonadism Market (2017-2032) by Type
15.3.1 Market Overview
15.3.2 Primary Hypogonadism
15.3.3 Secondary Hypogonadism
15.4 China Male Hypogonadism Market (2017-2032) by Diagnosis
15.4.1 Market Overview
15.4.2 Blood Tests
15.4.3 Imaging Scans
15.4.4 Genetic Testing
15.4.5 Clinical Evaluation
16 Regulatory Framework
16.1 Regulatory Overview
16.2 US FDA
16.3 EU EMA
16.4 Japan PMDA
16.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Lipocine Inc.
22.1.1 Financial Analysis
22.1.2 Type Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Pfizer Inc
22.2.1 Financial Analysis
22.2.2 Type Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 AbbVie Inc
22.3.1 Financial Analysis
22.3.2 Type Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Aytu BioPharma Inc.
22.4.1 Financial Analysis
22.4.2 Type Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Merck & Co., Inc.
22.5.1 Financial Analysis
22.5.2 Type Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Laboratoires Genevrier
22.6.1 Financial Analysis
22.6.2 Type Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Ferring
22.7.1 Financial Analysis
22.7.2 Type Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Perrigo Company plc
22.8.1 Financial Analysis
22.8.2 Type Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Eli Lilly
22.9.1 Financial Analysis
22.9.2 Type Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Bayer AG
22.10.1 Financial Analysis
22.10.2 Type Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Endo International plc.
22.11.1 Financial Analysis
22.11.2 Type Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Allergan plc
22.12.1 Financial Analysis
22.12.2 Type Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Bristol-Myers Squibb Company
22.13.1 Financial Analysis
22.13.2 Type Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 AstraZeneca PLC
22.14.1 Financial Analysis
22.14.2 Type Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 IBSA Institute Bio Chimique SA
22.15.1 Financial Analysis
22.15.2 Type Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
List not exhaustive
23 Male Hypogonadism Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 3.6% during the forecast period of 2024-2032, driven by the rising prevalence of male hypogonadism, and elderly population base across the 8 major markets.
The market demand is driven by the rising disposable income and advancement in the healthcare sector.
One of the significant trends in the market is the surge in approvals from the health regulatory agencies. In October 2023, Aurobindo Pharma's subsidiary Eugia Pharma Specialities Limited received final approval from the United States FDA to produce and commercialize Testosterone Cypionate injection.
Based on the type, the market is divided into primary hypogonadism and secondary hypogonadism.
Drug delivery methods include topical gels, injectables, transdermal patches, and others.
The market offers therapies such as testosterone replacement therapy, selective estrogen receptor modulators (SERMs), hormone replacement therapy, and assisted reproductive technologies (ART).
Major end users of the market are hospitals and clinics, specialty clinics, retail pharmacies, and other healthcare facilities.
Diagnostic methods available in the market include blood tests, imaging scans, genetic testing, and clinical evaluation.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are Lipocine Inc., Pfizer Inc., AbbVie Inc., Aytu BioPharma Inc., Merck & Co., Inc., Laboratoires Genevrier, Ferring, Perrigo Company plc, Eli Lilly, Bayer AG, Endo International plc., Allergan plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and IBSA Institute Bio Chimique SA.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER